- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: PSMA-18F DCFPyL Changes Treatment for PCa Recurrence in Significant Number of Patients with Low PSAs
In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.
The use of PSMA-18F DCFPyL may be more advantageous than conventional imaging in detecting biomechanical recurrence of prostate cancer in patients with low prostate-specific antigen (PSA) values, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
For the retrospective study, researchers evaluated the use of PET PSMA-18F DCFPyL (Pylarify, Lantheus) in 85 patients (mean age of 69) who had occult prostate cancer recurrence and PSA values less than 2 ng/mL. All patients in the cohort had negative computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET)-choline exams, according to the study authors.
At a six-month follow-up, the researchers found that PET imaging with PSMA-18F DCFPyL led to treatment changes in 75 percent of patients with positive findings (31/41).
Here one can see PET/CT imaging with PSMA-18F DCFPyL that led to modification with a planned radiotherapy treatment for recurrent prostate cancer. (Images courtesy of SNMMI.)
“In PET-PSMA-positive patients, the therapeutic changes found were classified as indicating or changing the planning of salvage radiotherapy treatment and/or initiating systemic treatment with hormone therapy,” noted lead study author Pedro Jose Plana Lopez, M.D., who is affiliated with Hospital Del Mar in Barcelona, Spain, and colleagues.
The study authors noted a median PSA level of 0.08 ng/dL after treatment changes were instituted in patients with positive PET PSMA results.
(Editor’s note: For related content, see “Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?,” “Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence” and “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer.”)
“PET-PSMA is a powerful diagnostic tool for patients with occult biochemical recurrence with PSA < 2ng/mL,” added Lopez and colleagues.
Reference
1. Lopez PJP, Amorelli FG, Cano JSB, et al. PET/CT PSMA-18F DCFPyL promotes treatment changes in occult biochemical recurrence of prostate carcinoma even with low PSA values. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 9, 2024.
Could MRI-Based AI Offer Better Risk Stratification for Prostate Cancer than PI-RADS?
July 3rd 2024The combination of deep learning assessment of prostate MRI with PI-RADS classification at a 15 percent risk threshold spared 49 percent of biopsies in comparison to 37 percent employing a PI-RADS>4 only cut-ff approach, according to new research.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
What New Research Reveals About PSMA PET/CT and Oligorecurrent Prostate Cancer
June 27th 2024For patients with oligorecurrent prostate cancer, the use of PSMA PET/CT guidance for metastasis-directed therapy (MDT) provided over 19 months more median progression-free survival than choline PET/CT guidance, according to newly published research.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
Study Shows PET/CT is Superior to SPECT/CT in Managing Patients with Primary Hyperparathyroidism
June 21st 2024F18-choline PET/CT imaging guidance for minimally invasive parathyroidectomy (MIP) procedures led to a 29 percent higher percentage of normocalcemia at one month post-op in comparison to imaging guidance with Tc99m-sestaMIBI (MIBI) SPECT/CT, according to new research.
